末次GnRH拮抗剂与激动剂触发间隔对卵母细胞回收及成熟率的影响
这项回顾性队列研究纳入53例正常促性腺激素患者,分析末次GnRH拮抗剂给药至GnRH激动剂触发间隔与IVF结局的关系。平均间隔4.6±2.7小时(范围1-12小时),间隔与卵母细胞回收率(CC 0.02,P=0.89)及MII卵率(CC 0.006,P=0.96)均无相关性,多因素分析调整年龄和BMI后亦无关联。
要点
- 末次拮抗剂至激动剂触发间隔与卵母细胞回收率无相关性。
- 该间隔与MII卵母细胞率亦无相关性。
- 正常促性腺激素患者中激动剂触发效果不受该间隔影响。
核心结论
- 在正常促性腺激素患者中,无论末次拮抗剂与激动剂触发间隔如何,GnRH激动剂触发均可有效诱导LH峰及卵母细胞成熟与释放。
研究设计与样本
- 回顾性队列研究,纳入53例接受GnRH拮抗剂方案IVF的正常促性腺激素患者,单中心2019年6月至2020年2月,均使用GnRH激动剂触发。
主要发现
- 末次拮抗剂至激动剂触发平均间隔4.6±2.7小时(范围1-12小时)。
- 间隔与卵母细胞回收率无相关性(Spearman相关系数0.02,P=0.89)。
- 间隔与MII卵母细胞率无相关性(相关系数0.006,P=0.96)。
- 多因素分析调整年龄和BMI后,间隔与治疗结局无关联。
临床怎么用
- 临床中GnRH激动剂触发可不依赖于末次拮抗剂给药的具体时间间隔。
- 该发现可能简化治疗流程、提高患者便利性和依从性,但需随机临床试验确认。
局限性
- 回顾性研究设计,样本量53例,单中心。
- 研究仅覆盖拮抗剂半衰期内且间隔小于12小时的情况。
- 结论需随机临床试验进一步验证。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
RESEARCH QUESTION: Does the time interval between the last gonadotrophin-releasing hormone (GnRH) antagonist dose and the GnRH agonist trigger affect the efficacy of the trigger in IVF treatments? DESIGN: This retrospective cohort study involved 53 normogonadotrophic patients undergoing GnRH antagonist-based IVF cycles, in a single academic centre between June 2019 and February 2020, in whom a GnRH agonist was used for final ovulation triggering. RESULTS: The mean time interval between the last GnRH antagonist dose and GnRH agonist triggering was 4.6 ± 2.7 h (range 1-12 h). There was no correlation between the antagonist-agonist interval and the oocyte recovery rate (Spearman's correlation coefficient [CC] 0.02, P = 0.89) or metaphase II oocyte rate (CC 0.006, P = 0.96). On multivariate analysis, the antagonist-agonist interval was not associated with treatment outcomes, after adjusting for the women's age and body mass index. CONCLUSIONS: This is the first study assessing the efficacy of the GnRH agonist trigger in relation to the time interval between the last GnRH antagonist dose and the agonist trigger within the first half-life of the GnRH antagonist and in less than 12 h. In normogonadotrophic patients, a GnRH agonist trigger can successfully induce an effective LH surge and oocyte maturation and release, irrespective of the time interval between the last antagonist dose and the agonist trigger. Once confirmed by randomized clinical trials, these finding may simplify treatment, improve patients' convenience and promote patient adherence to treatment.
引用
- Horowitz E, Mizrachi Y, Farhi J, et al. Does the interval between the last GnRH antagonist dose and the GnRH agonist trigger affect oocyte recovery and maturation rates? Reprod Biomed Online. 2020. PMID: 32933850. doi:10.1016/j.rbmo.2020.08.004
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。